Retinoid-related orphan nuclear receptors (RORs) ␣ and ␥ (NR1F1, -3) are highly expressed in liver, adipose tissue, thymus, and brain and are involved in many physiological processes, such as circadian rhythm and immune function. Enzymes in the cytochrome P450 2C subfamily metabolize many clinically important drugs and endogenous compounds, such as the anticancer drug paclitaxel and arachidonic acid, and are highly expressed in liver. Here, we present the first evidence that RORs regulate the transcription of human CYP2C8. Overexpression of ROR␣ and ROR␥ in HepG2 cells significantly enhanced the activity of the CYP2C8 promoter but not that of the CYP2C9 or CYP2C19 promoters. Computer analyses, promoter deletion studies, gel shift assays, and mutational analysis identified an essential ROR-responsive element at Ϫ2045 base pairs in the CYP2C8 promoter that mediates ROR transactivation. Adenoviral overexpression of ROR␣ and -␥ significantly induced endogenous CYP2C8 transcripts in both HepG2 cells and human primary hepatocytes. Knockdown of endogenous ROR␣ and -␥ expression in HepG2 cells by RNA interference decreased the expression of endogenous CYP2C8 mRNA by ϳ50%. These data indicate that RORs transcriptionally upregulate CYP2C8 in human liver and, therefore, may be important modulators of the metabolism of drugs and physiologically active endogenous compounds by this enzyme in liver and possibly extrahepatic tissues where RORs are expressed.
identified an essential ROR-responsive element at Ϫ2045 base pairs in the CYP2C8 promoter that mediates ROR transactivation. Adenoviral overexpression of ROR␣ and -␥ significantly induced endogenous CYP2C8 transcripts in both HepG2 cells and human primary hepatocytes. Knockdown of endogenous ROR␣ and -␥ expression in HepG2 cells by RNA interference decreased the expression of endogenous CYP2C8 mRNA by ϳ50%. These data indicate that RORs transcriptionally upregulate CYP2C8 in human liver and, therefore, may be important modulators of the metabolism of drugs and physiologically active endogenous compounds by this enzyme in liver and possibly extrahepatic tissues where RORs are expressed.
The human CYP2C subfamily consists of four genes: CYP2C8, CYP2C9, CYP2C18, and CYP2C19. CYP2C18 does not seem to be expressed at the protein level. The other three CYP2C enzymes metabolize approximately 20% of currently used clinical drugs, including the antidiabetic drugs tolbutamide and rosiglitazone, the anticoagulant drug warfarin, the anticonvulsant phenytoin, the antiulcer drug omeprazole, the anticancer drug paclitaxel, and numerous nonsteroidal antiinflammatory drugs, such as ibuprofen (Goldstein, 2001) . They are also involved in the oxidative metabolism of endogenous compounds, such as arachidonic acid and retinoic acid.
It is well known that there is marked variability in the metabolism of CYP2C substrates in human populations because of the occurrence of genetic polymorphisms in the CYP2C genes. The expression of CYP2C enzymes also has been reported to be induced by various drugs, including rifampicin, hyperforin (the active constituent in St. John's Wort), phenobarbital, and dexamethasone (Raucy et al., 2002; Madan et al., 2003; Komoroski et al., 2004) . This induction further amplifies the individual variability in drug metabolism in human populations and may lead to a change in the half-life of drugs and then eventually result in drug tolerance or therapeutic failure.
A number of nuclear receptors have been discovered to play important roles in the mediation of transactivation of P450 enzymes. In many cases, these nuclear receptors bind ligands, which may be involved in initiating translocation of the receptor to the nucleus, where the receptor binds to responsive elements within gene promoters and recruits coactivators to affect chromatin structure and increase the transcription of target genes (Handschin and Meyer, 2003) . Studies from our laboratory and other laboratories have revealed that several nuclear receptors that mediate druginduced transactivation of CYP2C9, -2C8, and -2C19 genes include the constitutive androstane receptor (CAR), the pregnane X receptor (PXR), and the glucocorticoid receptor (Gerbal-Chaloin et al., 2002; Chen et al., 2003 Chen et al., , 2004 Fergu-son et al., 2005) . On the other hand, the constitutive regulation of the CYP2C genes is believed to be regulated in liver by receptors that include the hepatic nuclear factor (HNF) 4␣, HNF3␥, and CCAAT/enhancer-binding protein (Jover et al., 1998 (Jover et al., , 2001 Bort et al., 2004; Chen et al., 2005) . HNF4␣ also seems to cross-talk with CAR/PXR, which binds to more distal CAR/PXR-responsive elements to achieve synergistic activation with CAR and increase PXR-mediated induction by rifampicin .
Another family of receptors, the retinoic acid receptorrelated orphan receptors, consists of three members, ROR␣, -␤, and -␥ (Jetten and Joo, 2006) . Several isoforms with varying lengths of the N terminus occur because of alternative promoter usage. They bind as a monomer to ROR-responsive elements (ROREs) consisting of a 6-bp AT-rich sequence preceding the half-core PuGGTCA motif and act as either transcription activators or repressors, depending on which cofactors are recruited. Studies from ROR knockout mice have revealed that these receptors exhibit critical roles in a number of physiological and pathological processes, including cerebellar ataxia, inflammation, atherosclerosis, immune response, and circadian rhythm (Jetten and Joo, 2006) . Recent studies have shown that the levels of several phase I and II enzymes, including Cyp2c70, Cyp2c39, and Cyp7b1, were altered in livers of ROR␣ and ROR␥ knockout mice, indicating that RORs may be a new regulator for P450 enzymes (Kang et al., 2007) . Wada et al. (2008) further demonstrated that ROR␣ could bind to the murine Cyp7b1 promoter to directly transactivate this gene.
In humans, ROR␣1, -␣4, and -␥1 are the forms expressed in liver, but only a few hepatic genes, including apolipoprotein C-III (ROR␣1) (Jetten and Joo, 2006) , apolipoprotein A5 (ROR␣1 and -␣4) (Genoux et al., 2005) , and hepatic synthesis of the plasma protein B-fibrinogen (Chauvet et al., 2005) have been identified as ROR␣1 and -␣4 targets. Because recent knockout studies indicated several murine P450 genes may be targets for ROR regulation in liver (Kang et al., 2007) , we hypothesized that RORs might also be transcriptional modulators of human P450 genes, contributing to the regulation of gene expression in liver and various extrahepatic tissues. In this study, we investigated the regulation of human CYP2C8, -2C9, and -2C19 genes by ROR␣1, ROR␣4, and ROR␥1. We provide experimental evidence showing that both ROR␣ and ROR␥ up-regulate the transcription of CYP2C8 in HepG2 cells, human primary hepatocytes, and Caco-2 cells by activating the CYP2C8 promoter directly through binding an RORE in the promoter region. The observations suggest an important role for RORs in the regulation of CYP2C8 expression in human liver and, as a consequence, a role in drug metabolism.
Materials and Methods
Promoter Constructs and Expression Plasmids. The wildtype CYP2C9-2923 , CYP2C8-2966 , CYP2C8-2527 , and CYP2C19-2.7k/pGL3_Basic constructs were as described previously (Chen et al., 2003; Ferguson et al., 2005) . Of the CYP2C8 promoter region, Ϫ2 and Ϫ1.5 kb were amplified by PCR and constructed into pGL3_Basic to yield 2C8-2k and -1.5k promoter constructs (Ferguson et al., 2005) . CYP2C8-2966 was used as the template to produce two mutants (CYP2C8-2966 /-2289m and CYP2C8-2966 ) by using QuikChange Site-directed mutagenesis (Stratagene, La Jolla, CA) and a deletion construct, CYP2C8-2966/⌬BglII, by BglII digestion.
The forward primers utilized for mutagenesis are as follows (the hexamer half-sites are indicated by boldface capital letters and mutated nucleotides are underlined): distal RORE mutation, 5Ј cttttattctataaAAAGAAACCTCAaggcagg 3Ј; and proximal RORE-mutation, 5Ј ccaaacacgtcTGAGGCACATTTtactc 3Ј. DNA sequencing was performed for all constructs to verify the mutations and to assure that no spurious mutations occurred.
The cDNAs of mouse ROR␣4 (Y08640), ROR␥1 (NM_011281), ROR␥2 (AF163668), and human ROR␣1 (NM_134261) were prepared by RT-PCR and inserted into p3XFLAG-CMV.7.1 (SigmaAldrich, St. Louis, MO) to produce the wild-type expression plasmids for transient transfection. We used murine ROR␣4, -␥1, and -␥2 expression plasmids for these studies because the amino acid identity between human and murine RORs is as high as 97% for ROR␣ proteins and 89% for ROR␥ proteins, and their biological effects are very similar. Moreover, we had constructed several DNA binding mutants and AF2 deletion mutants of the murine ROR␣ and -␥. The wild-type murine ROR expression constructs were used as the templates to produce three mutants: ROR␣4C13A, which has no DNA binding ability; ROR␥1⌬AF2 [deletion of Pro496 through the C terminus (20 amino acids including the AF2 domain, PPLYKELFSTD-VESPEGLSK)]; and ROR␥2⌬AF2, which has the same deletion as ROR␥1⌬AF2. To generate the ROR expression plasmids for in vitro transcription and translation, the cDNA of mouse ROR␣4 was cloned into pTRIamp18 (Ambion, Austin, TX), whereas the cDNAs of mouse ROR␥1 and human ROR␣1 were constructed into pcDNA3.1 (Invitrogen, Carlsbad, CA).
Cell Culture and Transfection. HepG2 and Caco-2 cells were maintained in minimum essential medium supplemented with 10 to ϳ20% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and antibiotics at 37°C and under 5% CO 2 . For transient transfection, cells were seeded into a 24-well plate at a density of 10 5 /well the day before transfection. To examine the activation of CYP2C8 promoters by RORs, an Effectene transfection kit (QIA-GEN, Valencia, CA) was used to complete transient transfections in HepG2 cells with CYP2C promoter constructs and pGL3_Basic, along with the internal control pRL-thymidine kinase promoter. Expression constructs for nuclear receptors or empty expression plasmids were cotransfected in parallel. The total amount of transfected plasmids was 200 ng/transfection. Twenty-four hours later, medium was changed, and cells were maintained for another day, followed by dual luciferase assays (Promega, Madison, WI). Firefly luciferase activities were normalized to Renilla luciferase readings to calculate relative promoter activity. Analogous procedures were used for the examination of other deleted and mutated promoter constructs.
Gel Shift Assays. ROR␣4, -␣1, and -␥1 were synthesized in vitro using the TNT T7 Quick Coupled Transcription Translation System (Promega), following the manufacturer's protocol. The empty expression vector was used as control. Gel shift assays were performed essentially as described previously (Medvedev et al., 1996) . To decrease the nonspecific binding, 1 g of sonicated salmon sperm DNA and 1 g of single-strand DNA were added to the incubation mixture. The following oligonucleotides were used as probes, wild-type, or mutated specific cold competitors. The hexamer half-sites are indicated by boldface capital letters, and mutated nucleotides are underlined:
CYP2C8-2045ROREmut, 5Ј-ctag-GTCTGAGGCACATTTTAC-3Ј; CYP2C8-2045ROREmut2, 5Ј ctag-GTCTGACCCACGTTTTAC-3Ј; and mouse Purkinje cell protein-2, 5Ј-ctagGTTATAGTAACTGGGTCAGGGGACTC-3Ј.
Adenovirus Preparation and Infection. cDNA of FLAGmROR␣4 (murine ROR␣4) and FLAG-mROR␥1 (murine ROR␥1) were used to prepare ROR adenoviruses for overexpression in HepG2 cells by using AdEasy-technology (Qbiogene Inc., Irvine, CA). Adenoviral infection was performed in HepG2 cells with adenoviruses LacZ
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and ROR␣4 or GFP/␤-Gal and ROR␥1 (1000 particles/cell) for 1 to 4 days, followed by total RNA isolation with an RNeasy Mini kit (QIAGEN). Human primary hepatocytes purchased from CellzDirect/ Invitrogen (Carlsbad, CA) were cultured in Williams' medium E (Sigma-Aldrich) complemented with 1ϫ ITSϩ supplement (SigmaAldrich; containing 10 g/ml insulin from bovine pancreas, 5.5 g/ml human transferrin, 5 ng/ml sodium selenite, 0.5 mg/ml bovine serum albumin, and 4.7 g/ml linoleic acid), 15 mM HEPES, 2 mM Lglutamine, 10 nM dexamethasone, and penicillin (50 U/ml)/streptomycin (50 g/ml). Hepatocytes were infected by viruses for 60 h, and total RNA was isolated for quantitative RT-PCR to measure mRNA concentration for CYP2C8, murine and human ROR␣, murine and human ROR␥, and TBP as the endogenous control.
Quantitative RT-PCR. Total RNA was extracted using an RNeasy Mini prep system (QIAGEN). RT-PCR analysis was performed in two steps by initial reaction with Moloney murine leukemia virus reverse transcriptase (Applied Biosystems, Foster City, CA). PCR with Taqman Universal PCR Master Mix (Applied Biosystems) was then performed with gene-specific primers using relative quantification methods (2 Ϫ⌬Ct ) and measured on an Applied Biosystems 7900HT Sequence Detection System using Taqman probes for CYP2C8, ROR␣, ROR␥, HNF4␣, GAPDH, mROR␣, mROR␥, and the endogenous control TBP.
Western Blot Analysis. To analyze the exogenous ROR protein expression in HepG2 cells, whole-cell lysates were prepared from HepG2 cells infected with control GFP virus or adenoviruses containing the different FLAG-tagged RORs in six-well plates by using radioimmunoprecipitation assay buffer (Promega). Equal volumes of lysates were subjected to 4 to 12% NuPAGE gel electrophoresis (Invitrogen), transferred to nitrocellulose membranes, and blocked with 5% nonfat milk blocking buffer. Horseradish peroxidase-conjugated monoclonal anti-FLAG antibody (Sigma-Aldrich) was used for immunoblotting at room temperature for 1 h, and then the membrane was washed six times. Detection was achieved using a Super Signal West Femto kit (Pierce Chemical, Rockford, IL).
Reduction of Endogenous Gene Expression by Small Interference RNAs. To reduce endogenous ROR expression in HepG2 cells, cells were seeded into a 24-well plate (10 5 /well) and transfected the next day with small interference RNAs (siRNAs) against human ROR␣ and ROR␥ (Dharmacon RNA Technologies, Lafayette, CO) at two doses of 50 and 100 nM following the instructions for Dharma-FECT 4 transfection reagent. Nonspecific siRNA and siRNA against GAPDH were transfected at the same time as the negative and positive controls, respectively. Twenty-four hours after transfection, cells were harvested, and total RNAs were isolated. Quantitative RT-PCR was performed to analyze mRNA levels of human ROR␣, ROR␥, GAPDH, and CYP2C8.
Statistical Analysis. Statistical analysis was performed in SigmaStat version 3.5 (Systat Software, Inc., San Jose, CA) using either one-or two-way analysis of variance as appropriate; subsequent pair-wise comparisons were made using the Bonferroni t-test method.
Results
RORs Specifically Transactivate the CYP2C8 Promoter in HepG2 Cells. To examine whether RORs can activate the transcription of human CYP2C genes, expression plasmids for the murine nuclear receptors ROR␣4 and ROR␥1 were cotransfected into HepG2 cells along with the luciferase promoter constructs CYP2C9-2923, CYP2C8-2966, CYP2C19-2.7k , or the empty luciferase vector pGL3_Basic. Among the CYP2C promoters, only the CYP2C8-2966 promoter was strongly activated by ROR␣4 and ROR␥1 (13-and 9-fold, respectively, p Ͻ 0.001), whereas the CYP2C9 and CYP2C19 promoters showed no response to exogenous RORs (Fig. 1A) . The nonresponsiveness of the CYP2C9 and CYP2C19 promoters to ROR was confirmed using 12-kb upstream promoter constructs for these two genes in transfection assays in HepG2 cells (data not shown). To confirm the specificity of activation of the CYP2C8 promoter by RORs, we cotransfected HepG2 cells with CYP2C8 promoter constructs and expression plasmids containing two ROR mutants and wild-type ROR␣4, ROR␥1, and ROR␥2. The mutant ROR␣4C13A harbors a mutation at its DNA binding domain and does not bind to ROR-responsive elements in DNA, whereas in ROR␥2⌬AF2, the AF2 domain is truncated and, therefore, unable to recruit coactivators. As shown in Fig. 1B , wild-type ROR␣4, ROR␥1, and ROR␥2 significantly elevated the activity of CYP2C8 promoter (p Ͻ 0.001), whereas the two mutants had no significant effect on promoter activity. These data further confirm that the CYP2C8 promoter is transactivated by ROR␣4, ROR␥1, and ROR␥2. We then examined the effect of progressive deletions of the CYP2C8 promoter construct (Fig. 1C) on ROR-mediated transactivation to identify the region in the CYP2C8 promoter that mediates ROR activation. As shown in Fig. 1D , significant ROR activation of CYP2C8 was observed with the CYP2C8-2966 and CYP2C8-2527 constructs (p Ͻ 0.001), but not with CYP2C8-2k and -1.5k constructs, suggesting that ROREs within the 500-bp fragment from Ϫ2.5 to Ϫ2 kb of the CYP2C8 promoter are responsible for this transactivation. We also created a construct in which the distal and proximal promoter regions were retained, but the middle region including this 500-bp fragment was deleted; no ROR activation was observed with the deletion construct. This result further supports the hypothesis that the localization of the functional RORE(s) is within the 500-bp promoter fragment identified above.
Identification of Two Putative ROREs That Are Required for ROR Activation of the CYP2C8 Promoter. With the sequence of the core motif for RORE, (A/T) 6 -AGGTCA, we performed a computer search (Motif/Vector NTI) for putative ROREs within the 3 kb of the CYP2C8 promoter and found two putative ROREs at Ϫ2289 and Ϫ2045 bp, respectively. Both sites are localized within the 500-bp promoter region identified above. Therefore, gel shift assays were performed to determine whether these two putative ROREs bind ROR in vitro. As displayed in Fig. 2B , transcribed and translated in vitro ROR␣4 products formed strong complexes with the 32 P-labeled oligonucleotide probe CYP2C8-2045RORE (lane 15) and with the positive control, a known RORE previously characterized from the murine Purkinje cell protein-2 (m-pcp-2) gene (lane 3), whereas products transcribed and translated in vitro from the empty pCR3.1 vector (V) did not produce any specific bands (lanes 2, 6, and 14 for all radiolabeled probes). In vitro-synthesized ROR␣4 exhibited a much weaker affinity for the 2C8-2289RORE, despite the fact that 10ϫ reactive probe was added to the gel (Fig. 2B, lane 7) . Preincubation with 5ϫ or 50ϫ excess of wild-type cold competitor ROREs effectively competed out the formation of all of these complexes (see lane 4 for m-pcp-2; lanes 8, 9, and 12 for 2C8-2289RORE; and lanes 16, 17, and 20 for 2C8-2045) , but mutated cold ROREs were unable to compete for these complexes (lanes 10 and 11 for 2C8-2289RORE, lanes 18 and 19 for 2C8-2045RORE). In vitro-transcribed ROR␥1 also bound both the positive control m-pcp-2 probe and the 2C8-2045RORE (Fig. 2C, lanes 3 and  15) . Again, the wild-type cold probes could effectively com-pete out the formation of these complexes (see lane 4 for m-pcp-2 and lanes 16, 17 and 20 for 2C8-2045RORE), whereas mutated ROREs did not (lanes 18 and 19) , showing the specificity of these complexes. We could not detect complex formation between the 2C8-2289RORE and the in vitrotranscribed ROR␥1.
To further examine the binding of RORs to the 2C8-2045RORE, antibody against ROR␣ and goat IgG was included in the incubation mixture before the addition of hot probes. A supershifted complex with retarded mobility was observed with the specific ROR␣ antibody, as shown by the arrow (Fig. 3A, lane 16 ), but not with control IgG (lane 15). We also saw a supershift with ROR antibody to the positive mouse pcp control (Fig. 3A, lane 6) . These results demonstrate the existence of ROR␣ in these complexes. Introduction of one mutation in the 2C8-2045RORE oligo (2C8-2045m2) (shown in Fig. 2A ) resulted in severe impairment in its ability to compete for the binding to RORs (Fig. 3A , lanes 13 and 14 for ROR␣4 and lanes 22 and 23 for ROR␥1). Another splicing variant, ROR␣1, is known to be expressed well in human liver and HepG2 cells (Chauvet et al., 2002) . In Fig. 3B , gel shift assays clearly show that ROR␣1 could also bind to both ROREs within the CYP2C8 promoter, although the proximal site again showed higher affinity. The complex could be supershifted by antibody to ROR␣. Taken together, these data clearly show that both ROREs can interact with RORs but that the 2C8-2045RORE has a much stronger affinity for both ROR␣ and ROR␥ than the 2C8-2289RORE.
To functionally investigate the roles of these two putative ROREs in the activation of CYP2C8 by RORs, we analyzed the effect of mutations within the two putative ROREs (Fig.  4A ) on ROR-mediated activation of the CYP2C8 promoter in HepG2 cells by transient transfection assays. As shown in Fig. 4B , mutation of the Ϫ2289RORE did not significantly affect the activation of CYP2C8, either by murine ROR␣4 or -␥1, whereas mutation of the Ϫ2045RORE almost totally abolished the transactivation of the CYP2C8 promoter by ROR␣4 and ROR␥1. In contrast to wild-type ROR, the ROR␣4 mutant did not significantly increase the activity of the CYP2C8 promoter (p Ͻ 0.01), whereas the ROR␥1 mutant had much less activity than wild-type ROR␥1. Because ROR␣1 selectively transactivates the ApoIII promoter in human colon carcinoma Caco-2 cells (but not in HepG2 cells), we compared the transactivation of the CYP2C8 promoter by human ROR␣1 in HepG2 cells and Caco-2 cells. As shown in Fig. 4 , C and D, the activity of the CYP2C8 promoter was increased similarly by ROR␣1 (p Ͻ 0.001) in both cell lines, and the mutation of the proximal RORE, but not the distal one, completely abolished this activation. Similar activation of the CYP2C8 promoter by ROR␣4 and ROR␥1 was also observed in Caco-2 cells (data not shown). These data are consistent with those from electrophoretic mobility shift assay and further indicate that the activation of the CYP2C8 Fig. 1 . ROR␣4 and -␥1 transactivate the CYP2C8 promoter but not the CYP2C9 or CYP2C19 promoters in HepG2 cells. A and B, promoter constructs in pGL3_Basic driven by CYP2C9, -2C8, and -2C19 promoters and empty vector were cotransfected into HepG2 cells along with the internal control pRL-thymidine kinase promoter. Expression vector containing the murine nuclear receptors ROR␣4, -␥1, -␥2, or their corresponding DNA binding mutant (ROR␣4C13A) and ROR␥2⌬AF2 (lacking the AF2 domain) were cotransfected into cells concomitantly. Twenty-four hours after transfections, cells were refreshed and maintained for another day, followed by cell lysis and luciferase activity assays. C and D, deletion constructs of CYP2C8 were similarly transfected with ROR␣4 or -␥1. ROR␣4, -␥1, or -␥2 increased CYP2C8 promoter activity compared with the empty vector ‫,ءءء(‬ p Ͻ 0.001). Neither of the ROR mutants activated CYP2C8 promoter activity. Values represent the means of three independent transfections Ϯ S.E.
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Endogenous CYP2C8 Was Elevated by Exogenous RORs in HepG2 Cells and in Human Primary Hepatocytes. We introduced exogenous murine ROR proteins into HepG2 cells to investigate their effects on the expression of endogenous CYP2C8. We prepared adenoviral constructs to overexpress wild-type mROR protein in HepG2 cells. CYP2C8 expression was measured for 4 days after infection. As confirmed in Western blots (Fig. 5, C and D) , both the wild-type ROR␣4 and -␥1 proteins were overproduced in HepG2 cells. Compared with the LacZ control, adenoviral overexpressed ROR␣4 significantly increased the level of endogenous CYP2C8 mRNA (p Ͻ 0.001) in a time-dependent manner. By the 4th day after infection, a 9-fold increase in the CYP2C8 mRNA level was observed compared with cells infected with LacZ (p Ͻ 0.001) (Fig. 5A) . Overexpression of ROR␥1 also increased endogenous CYP2C8 mRNA, reaching a 4-fold higher level by day 4 compared with the control adenovirus expressing GFP (p Ͻ 0.001). No change in CYP2C8 transcripts was observed in cells infected with the GFP control (Fig. 5B) .
Next, we examined whether exogenous RORs could elevate CYP2C8 expression in primary human hepatocytes. Adenoviruses expressing wild-type murine ROR␣4 and ROR␥1 were used to infect primary human hepatocytes for 60 h. The relative amount of endogenous hROR␣ mRNA (relative to TBP) was 5.2 Ϯ 0.1 in GFP-infected cells. After transfection, the level of mROR␣ expression was 200-fold higher (1209 Ϯ 131) than that of endogenous hROR␣. The amount of endogenous hROR␥ in GFP-infected cells was 1.8 Ϯ 0.2, whereas after transfection with mROR␥, ROR␥ levels were ϳ24 times higher (44 Ϯ 5). It should be noted that amino acid identity between human and murine RORs is ϳ97% for ROR␣ proteins and 89% for ROR␥ proteins, suggesting their biological effects should be very similar. Endogenous CYP2C8 mRNA was significantly increased, 5-fold by exogenous ROR␣4 and 7-fold by exogenous ROR␥1 (p Ͻ 0.001) (as shown in Fig. 6, A  and B) . The effects of exogenous ROR␣ and ROR␥ on CYP2C8 expression in HepG2 cells and primary hepatocytes suggest that RORs can activate the endogenous CYP2C8 gene in human liver.
Endogenous CYP2C8 Was Reduced by the Decrease in Endogenous RORs in HepG2 Cells. To gain more insight into the involvement of RORs in the transcriptional regulation of the CYP2C8 gene in vivo, we used siRNA technology to knock down endogenous ROR expression and examined its effect on endogenous CYP2C8 mRNA expression. siRNA oligos against human ROR␣ and ROR␥ were transfected into HepG2 cells individually or in combination at low and high doses. As shown in Fig. 7 , compared with transfection with the nontarget oligo, only the siRNAs that are specific for their target genes (ROR␣, ROR␥, and GAPDH) could Fig. 2 . Identification of the Ϫ2289 and Ϫ2045RORE within the CYP2C8 promoter by gel shift assays. A, sequences of the oligonucleotides used for the binding assay for Figs. 2 and 3 . Known or putative ROREs are written in bold and capital, the point mutations are underlined, and the nucleotides in lower case were added for labeling. B and C, 32 P-labeled probes for two putative ROREs within CYP2C8 (at Ϫ2289 and Ϫ2045 bp, respectively) and one control known RORE from m-pcp-2 were incubated at room temperature for 20 min with (ϩ) or without (Ϫ) in vitro-transcribed and -translated ROR proteins ROR␣4 (B) and ROR␥1 (C). Lanes 2, 6, and 14 (V) contained an in vitro translation transcription reaction carried out with empty vector rather than one carried out with vector containing an ROR. For competition analysis, 5ϫ or 50ϫ excess of various cold competitors (CCs) was added into binding reactions. The RORE at Ϫ2045 bp in the CYP2C8 promoter bound RORs much more strongly than the element at Ϫ2289 bp (B and C). Wild-type but not mutated cold competitors effectively competed for both elements showing the specificity of binding.
significantly reduce the mRNA levels of their targets; the siRNA for ROR␣ reduced endogenous ROR␣ mRNA specifically to 30% at the high dose 100 nM either used individually or in combination with siRNA for ROR␥ (p Ͻ 0.001) (Fig. 7A) . Endogenous ROR␥ mRNA was significantly reduced to 30% exclusively by its siRNA at the high dose (p Ͻ 0.001) (Fig.  7B ). ROR␣ and ROR␥ were decreased significantly more at the high dose of 100 nM siRNA than the low dose of 50 nM (p Ͻ 0.001). In accordance, CYP2C8 mRNA was reduced to 60% with the transfection of siRNA for ROR␣ alone at both doses (p Ͻ 0.01 with 50 nM and p Ͻ 0.001 with 100 nM) and to 65% with the transfection of siRNA for ROR␥ at the high dose of 100 nM (p Ͻ 0.01). However, it should be noted that the level of ROR␣ mRNA is approximately 3-fold higher than that of ROR␥ in HepG2 control cells, which is consistent with the slightly greater effect of knockdown of ROR␣ on CYP2C8 Fig. 3 . Binding of ROR␣1 and ROR␣4 to the Ϫ2289 and Ϫ2045 ROREs within the CYP2C8 promoter by gel shift assays and supershifts with ROR␣ antibody. 32 P-labeled probes for the two CYP2C8 ROREs and the control RORE (m-pcp-2) were incubated at room temperature for 20 min with (ϩ) or without (Ϫ) in vitro-transcribed and -translated ROR proteins (A, ROR␣4 and ROR␥1; B, ROR␣1) as described in Fig. 2 . Wild-type but not mutated cold competitors effectively competed for both elements confirming the specificity of the binding. Antibody against ROR␣ caused a supershift (SS) of the ROR␣4 complex with both m-pcp-2 (A, lane 6) and the Ϫ2045 RE (A, lane 16), whereas IgG did not (lanes 5 and 15). The supershifts were also formed with the complex with ROR␣1 by ROR␣ antibody (B, lanes 9 and 18). The RORE at Ϫ2045 bp in the CYP2C8 promoter bound ROR␣1 much more strongly than the element at Ϫ2289 bp.
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Discussion
In the present study, we show that the 3 kb of the human proximal CYP2C8 promoter is specifically activated by ROR␣1, ROR␣4, and ROR␥1 in HepG2 cells, the forms of ROR known to be expressed in human liver. In contrast, neither the CYP2C9 nor CYP2C19 promoters are activated by RORs, which was confirmed with both 3-and 12-kb promoter constructs. Two putative ROREs were identified and shown to interact specifically with ROR␣1, -␣4, and -␥1 proteins in gel shift assays; however, the proximal site at Ϫ2045 bp showed a much stronger affinity for all three isoforms than the more distal site. Mutation of the ROREs showed that only the proximal site plays a role in activation of the CYP2C8 promoter by RORs. In addition, endogenous CYP2C8 mRNA expression was up-regulated by exogenous ROR␣ and -␥ proteins in both HepG2 cells and primary hepatocytes. siRNA studies were able to achieve 70% knockdown of ROR␣ and ROR␥ isoforms in HepG2 cells in the present study. Double knockdown of ROR␣ and -␥ isoforms produced a 50% decrease in CYP2C8 mRNA. These knockdown studies might underestimate the role of RORs in liver somewhat because of the fact the knockdown of RORs receptors was not complete. The present study indicates that the ROR nuclear receptor family plays a role in regulating the expression of the human P450 gene CYP2C8 in liver and perhaps other tissues. In addition, constitutive levels of CYP2C8 are probably regulated to some extent by HNF4␣ in liver (Ferguson et al., 2005) .
The CYP2C8 enzyme oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. It is important in the metabolism of arachidonic acid to physiologically active compounds, such as epoxyeicosatrienoic acids (EETs) (Zeldin, 2001) . CYP2C8 is the principal enzyme responsible for the metabolism of clinically important drugs, such as the anticancer drug paclitaxel, the antimalarial drug amodiaquine, the antidiabetic drugs troglitazone and rosiglitazone, the antiarrhythmic drug amiodarone, and the calcium channel blocker verapamil (Totah and Rettie, 2005) . The discovery that CYP2C8 is transactivated by ROR␣ and -␥ in hepatocytes suggests the possibility Fig. 4 . Mutational analysis of the human CYP2C8 promoter constructs to functionally characterize the two putative ROREs at Ϫ2289 and Ϫ2045 bp. A, schematic representations of the wild-type and the RORE mutated promoter constructs for transfection. B, HepG2 cells were transfected by wild-type CYP2C8-2966-bp promoter constructs or one of two CYP2C8 promoter constructs containing mutations in ROREs at Ϫ2289 or Ϫ2045, respectively. Expression plasmids of wild-type murine ROR␣4, its DNA binding mutant ROR␣4C13A, wild-type ROR␥1, or a mutant lacking the AF2 domain (ROR␥1⌬AF2), were cotransfected concomitantly. HepG2 (C) or Caco-2 (D) cells were similarly transfected with normal CYP2C8 promoter constructs or constructs containing mutations at either RORE and expression plasmid containing wild-type human ROR␣1. Twenty-four hours after transfections, cells were refreshed and maintained for another day, followed by cell lysis and luciferase activity assays. Promoter constructs were transactivated by the wild-type cotransfected ROR␣1, -␣4, or -␥1 expression plasmids significantly compared with empty vector ‫,ءءء(‬ p Ͻ 0.001) but not the ROR␣4 DNA binding mutant and only slightly by the ROR␥ mutant lacking the AF2 domain. In contrast, transactivation was abolished when the Ϫ2045RORE was mutated. Values represent the means of three independent transfections Ϯ S.E.
that the clearance of these drugs might be modulated to some extent by ligands of RORs that modulate ROR activity. Recent X-ray crystal structure studies have demonstrated a series of natural compounds that can reversibly bind to ROR␣ and act as agonists increasing its transactivational activity (Kallen et al., 2002 (Kallen et al., , 2004 . These include cholesterol and its structural derivatives 7-dehydrocholesterol and cholesterol sulfates. For example, depletion of cholesterol by the drug lovastatin in the osteosarcoma cells U-20S in vitro has been proposed to modulate ROR␣ transcriptional activity (Kallen et al., 2002) . In addition, certain natural compounds, including several retinoids such as all-trans-retinoic acid and the synthetic retinoid ALRT1550 (Ligand Pharmaceuticals, San Diego, CA), can bind ROR␤ and ROR␥ and act as partial antagonists, inhibiting their transactivation activity (Stehlin-Gaon et al., 2003) .
Recent studies have implicated RORs in the control of circadian rhythm, both in the central nervous system (ROR␣ and -␤) (Jetten and Joo, 2006) and in peripheral tissues such as liver (ROR␣ and -␥) (Jetten and Joo, 2006) . In mammals, many physiological and behavioral processes exhibit daily oscillations, including many hepatic enzyme activities, including those involved in energy metabolism, and a clear link between the control of circadian rhythm and metabolism has been established (Albrecht, 2006; Hastings et al., 2007) . The clock oscillator consists of interlocked positive and negative transcriptional/posttranscriptional feedback loops between the clock genes Clock/Bmal1 and Per/Crys. By binding to the RORE within target gene promoters, RORs, along with the negative competitors Rev-Erb␣ and -␤, control the expression of Bmal1 (Jetten and Joo, 2006) . A number of rodent P450 enzymes display a daily fluctuation in their mRNA expression or catalytic activity, such as Cyp1a1 and 1b1, Cyp2a, Cyp2c, Cyp2e1, Cyp4a, Cyp7a1 and 7b1, and Cyp8b1 (Kang et al., 2007; Ohdo, 2007) . ROR␣ has been suggested to be involved in the oscillatory regulation of some of these P450 enzymes (Wada et al., 2008) . In humans, the effect of circa- Fig. 5 . Overexpression of murine ROR␣4 and ␥1 dramatically increases endogenous CYP2C8 mRNA in HepG2 cells. Adenoviruses containing FLAG-mROR␣4 and the control LacZ (A) or FLAG-mROR␥1 and the control GFP/␤-Gal (B) were utilized to infect HepG2 cells in triplicate for 1 to 4 days with a dose of 1000 particles/cell. Cells were harvested and used to isolate total RNA. cDNAs were synthesized with MMLV, and then real-time quantitative PCR analyses were performed to determine the expression of CYP2C8 and TBP. Endogenous CYP2C8 mRNA gradually increased after infection of HepG2 cells with adenoviruses containing ROR over those infected with LacZ significantly ‫,ءء(‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001). Data represent means Ϯ S.E. (n ϭ 9). All data are normalized to TBP levels. The same ROR viruses and the GFP control were used to infect HepG2 cells in six-well plate in duplicates. After 2 days, the whole-cell lysates were prepared, and the Western blot was performed to detect the expression of exogenous FLAG-tagged ROR protein (C and D). 6 . Overexpression of murine ROR dramatically elevated endogenous CYP2C8 mRNA in human primary hepatocytes. Human primary hepatocytes were infected with adenoviruses for FLAG-mROR␣4 (A) and FLAG-mROR␥1 (B) and the control GFP/␤-Gal at a dose of 1000 particles/ cell. Total RNA was isolated after 60 h, and real-time quantitative PCR analyses were performed to determine the expression of CYP2C8 relative to TBP. Both ROR viruses significantly increased endogenous CYP2C8 mRNA over the GFP adenoviral control (p Ͻ 0.001). Data represent means Ϯ S.E. (n ϭ 9). All data are normalized to TBP levels.
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at ASPET Journals on September 7, 2017 jpet.aspetjournals.org dian rhythm on drug metabolism has not been studied extensively. However, studies from Ohdo and colleagues have suggested that the effectiveness of drugs depends on the time of day at which they are administered (Kang et al., 2007; Ohdo, 2007) . Moreover, they showed that activity of CYP3A4 exhibits an ϳ2.8-fold diurnal variation in humans based on 6-hydroxycortisol/cortisol ratios, which are a noninvasive index of CYP3A4 activity (Ohdo, 2007) . It would not be surprising to find an oscillatory regulation in other human P450 enzymes such as CYP2C8 because the expression of a number of nuclear receptors, including RORs and HNF4␣, CAR, peroxisome proliferator-activated receptor, estrogen-related receptor, and small heterodimer partner, display circadian rhythm (Yang et al., 2006) . CYP2C8 is the one CYP2C member that has the broadest tissue expression. It has been found to be expressed primarily in liver but also exists in many other tissues such as brain, heart, endothelial cells, intestine, and kidney (Klose et al., 1999) . Both ROR␣ and ROR␥ are widely expressed in most of these tissues (Jetten and Joo, 2006) . This overlapping distribution is consistent with the possibility that RORs may also regulate CYP2C8 in some of these extrahepatic tissues. In brain, ROR␣ is expressed in many regions, including the thalamus and cerebellum, where it plays an important role in circadian rhythm. ROR␤ is also found in brain. CYP2C8 mRNA has been detected at relatively high levels in many regions in human brain, including cerebellum, although unlike ROR, the distribution of CYP2C8 has not been studied in different cell types in the brain using immunohistochemical approaches (McFayden et al., 1998; Klose et al., 1999) . ROR␣ is known to be expressed in small intestinal epithelium and in the human colon cell line Caco-2 (Jetten and Joo, 2006) . The present study demonstrates that the CYP2C8 promoter can be activated by ROR␣1 in Caco-2 cells, indicating a possible regulatory role of RORs in transcription of CYP2C8 in colon and intestine. mRNA of ROR␣ also has been detected in endothelial cells (Besnard et al., 2002) , where CYP2C8 oxidizes arachidonic acid to produce 11,12-and 14,15-EETs that have vasodilatory roles and anti-inflammatory roles (Wray and Bishop-Bailey, 2008) . If CYP2C8 expression is up-regulated by ROR␣1 in endothelial cells, this might increase EET formation, thus enhancing dilation and producing anti-inflammatory responses.
In summary, in the present study, we provide evidence demonstrating that ROR␣1, -␣4, and -␥1 positively regulate CYP2C8 gene expression in human hepatocytes through an RORE in the CYP2C8 proximal promoter region. Because CYP2C8 catalyzes the metabolism of a number of clinically important drugs, and RORs function as ligand-dependent transcription factors, ROR (ant)agonists may be able to control the expression of CYP2C8 and, therefore, the metabolism of these drugs. In addition, because RORs play a role in the regulation of circadian rhythm, they might play a role in the possible circadian regulation of CYP2C8.
